{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T08:32:56Z","timestamp":1726389176440},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s12185-018-2455-x","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T05:09:25Z","timestamp":1523509765000},"page":"167-175","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["EPOCH regimen as salvage therapy for adult T-cell leukemia\u2013lymphoma"],"prefix":"10.1007","volume":"108","author":[{"given":"Eo","family":"Toriyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Itonaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sawayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"issue":"3","key":"2455_CR1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481\u201392.","journal-title":"Blood"},{"issue":"12","key":"2455_CR2","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","volume":"77","author":"BJ Poiesz","year":"1980","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77(12):7415\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2455_CR3","doi-asserted-by":"publisher","first-page":"6476","DOI":"10.1073\/pnas.78.10.6476","volume":"78","author":"Y Hinuma","year":"1981","unstructured":"Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 1981;78:6476\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2455_CR4","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2455_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984\u201387). Br J Haematol. 1991;79:428\u201337.","journal-title":"Br J Haematol"},{"issue":"3","key":"2455_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia\u2013lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453\u20139.","journal-title":"J Clin Oncol"},{"key":"2455_CR7","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia\u2013lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458\u201364.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2455_CR8","first-page":"2159","volume":"54","author":"H Taniguchi","year":"2013","unstructured":"Taniguchi H, Imaizumi Y, Makiyama J, Itonaga H, Ando K, Sawayama Y, et al. Outcome of patients with relapsed\/refractory adult T-cell leukemia\u2013lymphoma after salvage therapy. Rinsho Ketsueki. 2013;54(12):2159\u201366.","journal-title":"Rinsho Ketsueki."},{"issue":"24","key":"2455_CR9","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570\u20137.","journal-title":"Blood"},{"issue":"21","key":"2455_CR10","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1200\/JCO.2000.18.21.3633","volume":"18","author":"M Gutierrez","year":"2000","unstructured":"Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18(21):3633\u201342.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2455_CR11","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","volume":"11","author":"WH Wilson","year":"1993","unstructured":"Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1993;11(8):1573\u201382.","journal-title":"J Clin Oncol"},{"key":"2455_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/annonc\/mdh093","volume":"15","author":"M Jermann","year":"2004","unstructured":"Jermann M, Jost LM, Taverna Ch, Jacky E, Honegger HP, Betticher DC, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004;15:511\u20136.","journal-title":"Ann Oncol"},{"issue":"4","key":"2455_CR13","first-page":"267","volume":"39","author":"N Dobashi","year":"1998","unstructured":"Dobashi N, Usui N, Kobayashi T, Yamazaki H, Asai O, Yano S, et al. EPOCH therapy for relapsed\/refractory lymphoid malignancies. Rinsho Ketsueki. 1998;39(4):267\u201372.","journal-title":"Rinsho Ketsueki."},{"issue":"4","key":"2455_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3816\/CLM.2001.n.003","volume":"1","author":"DD Wilder","year":"2001","unstructured":"Wilder DD, Ogden JL, Jain VK. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin\u2019s lymphoma. Clin Lymphoma. 2001;1(4):285\u201392.","journal-title":"Clin Lymphoma."},{"issue":"7","key":"2455_CR15","first-page":"799","volume":"99","author":"N Nagajothi","year":"2007","unstructured":"Nagajothi N, Dham SK, Gelfand Y, Sanmugarajah J. Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy. J Natl Med Assoc. 2007;99(7):799\u2013801.","journal-title":"J Natl Med Assoc"},{"issue":"1","key":"2455_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3325\/cmj.2017.58.40","volume":"58","author":"V Pej\u0161a","year":"2017","unstructured":"Pej\u0161a V, Prka Z, Lucijani\u0107 M, Mitrovi\u0107 Z, Pir\u0161i\u0107 M, Jak\u0161i\u0107 O, et al. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croat Med J. 2017;58(1):40\u20138.","journal-title":"Croat Med J."},{"issue":"2","key":"2455_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clml.2015.11.012","volume":"16","author":"ZS Lamar","year":"2016","unstructured":"Lamar ZS, Fino N, Palmer J, Gruber L, Morris BB, Raetskaya-Solntseva O, et al. Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) with or without rituximab as first-line therapy for aggressive non-Hodgkin\u2019s lymphoma. Clin Lymphoma Myeloma Leuk. 2016;16(2):76\u201381.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"20","key":"2455_CR18","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","volume":"369","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt\u2019s lymphoma. N Engl J Med. 2013;369(20):1915\u201325.","journal-title":"N Engl J Med"},{"key":"2455_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/(SICI)1097-0215(19990812)82:4<599::AID-IJC21>3.0.CO;2-R","volume":"82","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Oka M, Yamada Y, Soda H, Fukuda M, Kinoshita A, et al. Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes. Int J Cancer. 1999;82:599\u2013604.","journal-title":"Int J Cancer"},{"issue":"2","key":"2455_CR20","doi-asserted-by":"publisher","first-page":"e4420","DOI":"10.1371\/journal.pone.0004420","volume":"4","author":"L Ratner","year":"2009","unstructured":"Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia\u2013lymphoma. PLoS ONE. 2009;4(2):e4420.","journal-title":"PLoS ONE"},{"issue":"2","key":"2455_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/BF02983215","volume":"77","author":"K Tsukasaki","year":"2003","unstructured":"Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia\u2013lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77(2):164\u201370.","journal-title":"Int J Hematol"},{"key":"2455_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","volume":"113","author":"Y Yamada","year":"2001","unstructured":"Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-SCF-supported combination chemotherapy, LSG15, for adult T-cell leukemia\u2013lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375\u201382.","journal-title":"Br J Haematol"},{"key":"2455_CR23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","volume":"30","author":"H Katsuya","year":"2012","unstructured":"Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol. 2012;30:1635\u201340.","journal-title":"J Clin Oncol"},{"key":"2455_CR24","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3324\/haematol.2017.167742","volume":"102","author":"Y Maeda","year":"2017","unstructured":"Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102:2097\u2013103.","journal-title":"Haematologica"},{"key":"2455_CR25","first-page":"3625","volume":"9","author":"T Ishida","year":"2003","unstructured":"Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625\u201334.","journal-title":"Clin Cancer Res"},{"key":"2455_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia\u2013lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837\u201342.","journal-title":"J Clin Oncol"},{"key":"2455_CR27","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","volume":"34","author":"T Ishida","year":"2016","unstructured":"Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002. J Clin Oncol. 2016;34:4086\u201393.","journal-title":"J Clin Oncol"},{"key":"2455_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/BF02986621","volume":"77","author":"K Tobinai","year":"2003","unstructured":"Tobinai K, Uike N, Saburi Y, Chou T, Etoh T, Masuda M, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in R\/r adult T-cell leukemia\u2013lymphoma. Int J Hematol. 2003;77:512\u20137.","journal-title":"Int J Hematol"},{"key":"2455_CR29","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/bjc.1994.394","volume":"70","author":"H Tsuda","year":"1994","unstructured":"Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer. 1994;70:771\u20134.","journal-title":"Br J Cancer"},{"key":"2455_CR30","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/cas.12735","volume":"106","author":"K Ishitsuka","year":"2015","unstructured":"Ishitsuka K, Utsunomiya A, Katsuya H, Takeuchi S, Takatsuka Y, Hidaka M, et al. A phase II study of bortezomib in patients with r\/r aggressive adult T-cell leukemia\/lymphoma. Cancer Sci. 2015;106:1219\u201323.","journal-title":"Cancer Sci"},{"key":"2455_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/sj.thj.6200374","volume":"5","author":"O Hermine","year":"2004","unstructured":"Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma. Hematol J. 2004;5:130\u20134.","journal-title":"Hematol J."},{"key":"2455_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","volume":"155","author":"JL Berkowitz","year":"2014","unstructured":"Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, et al. Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma. Clin Immunol. 2014;155:176\u201387.","journal-title":"Clin Immunol."},{"key":"2455_CR33","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2169\/internalmedicine.54.1953","volume":"54","author":"N Kawano","year":"2015","unstructured":"Kawano N, Yoshida S, Kuriyama T, Tahara Y, Yamashita K, Nagahiro Y, et al. Clinical features and treatment outcomes of 81 patients with aggressive type adult T-cell leukemia\u2013lymphoma at a single institution over a 7-year period (2006-2012). Intern Med. 2015;54:1489\u201398.","journal-title":"Intern Med"},{"key":"2455_CR34","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426\u201333.","journal-title":"J Clin Oncol"},{"key":"2455_CR35","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12185-016-2087-y","volume":"104","author":"Y Tsubokura","year":"2016","unstructured":"Tsubokura Y, Satake A, Hotta M, Yoshimura H, Fujita S, Azuma Y, et al. Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia\/lymphoma: a report of two cases. Int J Hematol. 2016;104:744\u20138.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2455-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T05:32:34Z","timestamp":1571117554000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2455-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2455"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2455-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"assertion":[{"value":"7 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}